New Delhi, Jun 19 (PTI) Natco Pharma on Thursday said the US health regulator has issued a Form 483 with seven observations after inspecting its pharma division in Hyderabad.

The US Food and Drug Administration (USFDA) had conducted an inspection at the company's pharma division located in Kothur, Hyderabad, from June 9-19, 2025, Natco Pharma said in a regulatory filing.

Also Read | RRB NTPC Graduate Level Recruitment Exam 2025: Railway Recruitment Boards Release Exam City Slip for CBT 1 Examination at rrb.digialm.com, Know Steps To Download.

"On conclusion of the inspection, the company received seven observations in the Form-483," it said.

As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

Also Read | How To Apply for Voter ID Card Online and Track Application? All You Need To Know As Election Commission Rolls Out 15-Day EPIC Delivery.

Natco said it is confident that it will address the observations within the stipulated timeline and remains committed to being cGMP compliant and supplying high-quality products to its customers and patients globally.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)